Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Danaher Corp. pages available for free this week:
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Operating Profit Margin since 2005
- Price to Operating Profit (P/OP) since 2005
- Analysis of Revenues
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
An analysis of the financial ratios over the five-year period reveals several notable trends regarding profitability and efficiency.
- Gross Profit Margin
- The gross profit margin increased significantly from 55.98% in 2020 to a peak of 60.95% in 2021. It then slightly declined but remained relatively stable around 58.74%-60.21% through 2023 and 2024. This suggests consistent cost management at the production level with a minor downward adjustment after 2021.
- Operating Profit Margin
- Operating profit margin shows a marked improvement from 18.99% in 2020 to 27.61% in 2022, indicating enhanced operational efficiency or favorable operating leverage. However, this margin declined notably to 21.77% in 2023 and further to 20.37% in 2024, pointing to increased operating expenses or lower operating income in the latter years.
- Net Profit Margin
- The net profit margin follows a similar pattern to operating margin. It rose from 16.36% in 2020 to a high of 22.91% in 2022, reflecting strong bottom-line profitability. Conversely, a decline occurs afterward, dropping to 16.33% by 2024, which may be indicative of higher interest expenses, taxes, or other non-operational impacts reducing overall profitability.
- Return on Equity (ROE)
- The ROE increased substantially from 9.17% in 2020 to 14.39% in 2022, demonstrating effective use of shareholders’ equity to generate profits. However, the ratio reduced sharply thereafter, falling to 7.87% in 2024. This decline raises concerns about the company’s ability to maintain returns for equity holders in the most recent years.
- Return on Assets (ROA)
- ROA improved from 4.79% in 2020 to 8.55% in 2022, indicating better utilization of total assets in generating profits. Similar to ROE, it declined after 2022 to 5.03% in 2024, reflecting a decrease in asset efficiency or profitability relative to the asset base.
Overall, the data indicate robust growth and profitability improvements through 2022, followed by a period of decreasing margins and returns in the last two years. The simultaneous decline in both ROE and ROA in 2023 and 2024 suggests that the company faced challenges in sustaining its profitability and operational efficiency relative to both equity and asset investments during this period.
Return on Sales
Return on Investment
Gross Profit Margin
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Gross profit | ||||||
Sales | ||||||
Profitability Ratio | ||||||
Gross profit margin1 | ||||||
Benchmarks | ||||||
Gross Profit Margin, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Gross profit margin = 100 × Gross profit ÷ Sales
= 100 × ÷ =
2 Click competitor name to see calculations.
- Sales
- Sales exhibited a significant upward trend from 2020 to 2022, increasing from $22,284 million to $31,471 million. However, this growth was not sustained in the subsequent years, as sales declined sharply to $23,890 million in 2023 and remained relatively flat at $23,875 million in 2024.
- Gross Profit
- Gross profit followed a somewhat similar pattern to sales. There was strong growth from $12,475 million in 2020 to a peak of $18,949 million in 2022. This was followed by a substantial decrease to $14,034 million in 2023, with a marginal recovery to $14,206 million in 2024.
- Gross Profit Margin
- The gross profit margin showed improvement from 55.98% in 2020 to a peak of 60.95% in 2021, indicating increased efficiency or pricing power during that period. The margin slightly decreased to 60.21% in 2022, followed by a further decline to 58.74% in 2023. In 2024, the margin improved moderately to 59.5%, suggesting some stabilization in profitability relative to sales.
- Summary of Trends
- Overall, the data reveals a period of growth in both sales and gross profit through 2022, accompanied by elevated gross profit margins. The following two years show a marked contraction in top-line revenues and gross profit, coupled with a decline and partial recovery in profitability margins. This pattern suggests potential challenges impacting revenue generation and gross profit, though profitability ratios remained relatively resilient, with margins still near 60% in the later years.
Operating Profit Margin
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Operating profit | ||||||
Sales | ||||||
Profitability Ratio | ||||||
Operating profit margin1 | ||||||
Benchmarks | ||||||
Operating Profit Margin, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Operating Profit Margin, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Operating Profit Margin, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Operating profit margin = 100 × Operating profit ÷ Sales
= 100 × ÷ =
2 Click competitor name to see calculations.
The financial data reveals distinct trends in the company's operating profit, sales, and operating profit margin over the five-year period ending December 31, 2024.
- Operating Profit
- Operating profit shows a rising trend from 2020 to 2022, increasing steadily from $4,231 million in 2020 to a peak of $8,688 million in 2022. However, this upward trajectory reverses in 2023 and 2024, with values decreasing significantly to $5,202 million and then further to $4,863 million, respectively.
- Sales
- Sales follow a similar pattern to operating profit. The company experienced consistent growth from $22,284 million in 2020 to $31,471 million in 2022. Subsequently, sales declined sharply in 2023 to $23,890 million and remained relatively stable at $23,875 million in 2024.
- Operating Profit Margin
- The operating profit margin improved from 18.99% in 2020 to a high of 27.61% in 2022, indicating increasing efficiency or profitability during that period. Following 2022, the margin contracted to 21.77% in 2023 and further to 20.37% in 2024, reflecting decreased profitability relative to sales despite operating profits remaining positive.
Overall, the data delineates a phase of robust growth and margin expansion through 2022, followed by a period of contraction in both profitability and sales during 2023 and 2024. This shift might indicate market challenges, increased costs, or other operational factors impacting performance after the peak year.
Net Profit Margin
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings | ||||||
Sales | ||||||
Profitability Ratio | ||||||
Net profit margin1 | ||||||
Benchmarks | ||||||
Net Profit Margin, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Net Profit Margin, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Net Profit Margin, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Net profit margin = 100 × Net earnings ÷ Sales
= 100 × ÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends over the five-year period in question. The company's sales figures demonstrate a significant increase from 2020 to 2022, rising from approximately 22.3 billion US dollars to over 31.4 billion US dollars. However, in 2023 and 2024, sales declined sharply, falling back to levels close to those of 2020.
Net earnings follow a somewhat similar pattern but with greater volatility. Earnings increased substantially from about 3.6 billion US dollars in 2020 to a peak of approximately 7.2 billion US dollars in 2022. Subsequently, net earnings experienced a steep decline, decreasing to roughly 4.8 billion in 2023 and further down to about 3.9 billion US dollars in 2024, which is even lower than the starting point in 2020.
The net profit margin, which represents profitability relative to sales, increased steadily from 16.36% in 2020 to a high of 22.91% in 2022. This suggests that the company not only grew its revenue but also improved profitability during that period. However, from 2023 onward, the margin contracted significantly, declining to 19.94% in 2023 and further to 16.33% in 2024, nearly returning to the 2020 levels. This reversal corresponds with the decline in both sales and net earnings during the latter two years.
- Sales Trends
- Strong growth was evident through 2022, followed by a sharp decline in 2023 and stabilization around 2020 levels in 2024.
- Net Earnings Trends
- Net earnings more than doubled from 2020 to 2022, reaching the highest point in 2022, before decreasing substantially over the next two years.
- Profitability
- Net profit margin increased steadily through 2022 but contracted significantly afterward, indicating reduced efficiency or increased costs relative to sales in the last two years.
- Overall Interpretation
- The company exhibited strong growth and profitability improvements up to 2022, but both revenues and profitability declined markedly in the subsequent two years, suggesting challenges that impacted financial performance and efficiency.
Return on Equity (ROE)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings | ||||||
Total Danaher stockholders’ equity | ||||||
Profitability Ratio | ||||||
ROE1 | ||||||
Benchmarks | ||||||
ROE, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
ROE, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
ROE, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
ROE = 100 × Net earnings ÷ Total Danaher stockholders’ equity
= 100 × ÷ =
2 Click competitor name to see calculations.
- Net Earnings
- The net earnings of the company demonstrated a marked upward trend from 2020 to 2022, increasing from 3,646 million US dollars in 2020 to a peak of 7,209 million US dollars in 2022. This indicates significant profitability growth during this period. However, this was followed by a notable decline in net earnings in the subsequent years, falling to 4,764 million in 2023 and further decreasing to 3,899 million in 2024, suggesting challenges impacting profitability or one-time events affecting earnings during these later years.
- Total Danaher Stockholders’ Equity
- Stockholders’ equity consistently increased over the five-year period from 39,766 million US dollars in 2020 to a high of 53,486 million in 2023, reflecting an overall strengthening of the company’s net asset base. In 2024, equity declined slightly to 49,543 million, indicating a reduction in retained earnings or other equity components, possibly linked to the decreased net earnings in that year.
- Return on Equity (ROE)
- ROE mirrored the trends observed in net earnings, rising from 9.17% in 2020 to a peak of 14.39% in 2022, signifying enhanced efficiency in generating profit from shareholders’ equity. Subsequently, ROE decreased to 8.91% in 2023 and further to 7.87% in 2024, which points to diminished profitability relative to equity during these years. This decline may be related to the drop in net earnings despite the initially growing equity base.
Return on Assets (ROA)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings | ||||||
Total assets | ||||||
Profitability Ratio | ||||||
ROA1 | ||||||
Benchmarks | ||||||
ROA, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
ROA, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
ROA, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
ROA = 100 × Net earnings ÷ Total assets
= 100 × ÷ =
2 Click competitor name to see calculations.
- Net Earnings
- Net earnings displayed notable growth from 2020 to 2022, rising from $3,646 million to a peak of $7,209 million. This upward trend was followed by a decline in subsequent years, with earnings falling to $4,764 million in 2023 and further to $3,899 million in 2024.
- Total Assets
- Total assets increased steadily from 2020 through 2023, moving from $76,161 million to $84,488 million. However, there was a noticeable decrease in 2024, with total assets dropping to $77,542 million.
- Return on Assets (ROA)
- The return on assets followed a similar pattern to net earnings, improving from 4.79% in 2020 to a high of 8.55% in 2022. This was succeeded by a decline to 5.64% in 2023 and a further decrease to 5.03% in 2024, indicating reduced profitability relative to the asset base in the later years.